The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
from NDTV Profit - Latest https://ift.tt/2NQv31m
from NDTV Profit - Latest https://ift.tt/2NQv31m
Novartis Sickle-Cell Drug Gets US Approval
![Novartis Sickle-Cell Drug Gets US Approval]()
Reviewed by placements page
on
November 16, 2019
Rating:
No comments: